RAGE targeted strategies for Alzheimer’s amyloid β peptide induced blood brain barrier dysfunctions

2013

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.1186/1750-1326-8-s1-p5
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Background Blood-brain barrier (BBB) dysfunctions have been implicated in the development and progression of Alzheimer’s disease. Cerebral endothelial cells (CECs) and astrocytes are the main cell components of the BBB. Although amyloid-b oligomers have been reported to mediate oxidative damage to the CECs and astrocytes and trigger the downstream MAPK/ERK pathway, the cell surface binding site for Ab and exact sequence of these events have yet to be elucidated. In this study, the receptor for advanced glycation endproducts (RAGE) was postulated to function as a signal transducing cell surface receptor for Ab to induce ROS generation from NADPH oxidase and trigger downstream pathways for the phosphorylation of extracellular-signal-regulated kinases (ERK1/2) and cytosolic phosphorilase A2 (cPLA2).